Catalyst
Monitor outcomes related to the accuracy of survival estimates and recurrence risk predictions over the study duration.
Date
July 4, 2026
Phase
N/A
Status
watch
Signal score
7.0
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.